Physician profile
Ronald Mchose
NPI 1689645368
$6,209.02
in general payments reported to CMS, 2019-2025
36 companies · $29.69 in 2025
The $29.69 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $1,932 · 2021: $1,663 · 2022: $938 · 2023: $321 · 2024: $62.26 · 2025: $29.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $968.07 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $723.63 | 2019-2022 | |
| Lilly USA, LLC | $471.31 | 2019-2023 | Jardiance, Emgality |
| Abbvie INC. | $462.33 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.03 | 2019-2024 | Jardiance |
| Amgen INC. | $323.27 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $305.44 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $268.89 | 2019-2023 | Gardasil 9, Vaxneuvance |
| Allergan, INC. | $261.36 | 2019-2021 | |
| Novo Nordisk INC | $254.99 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $227.80 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.71 | 2019-2023 | Xifaxan, Trulance |
| Radius Health, INC. | $166.06 | 2019-2021 | |
| Glaxosmithkline, LLC. | $155.00 | 2020-2022 | |
| Nevro Corp. | $150.00 | 2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mchose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.